乳腺癌骨转移患者18F-FDG摄取的可重复性及其对临床试验入组的意义
本研究前瞻性评估乳腺癌骨优势转移患者18F-FDG摄取的重测变异,第一队列9例38处骨病灶在14天内两次显像,SUVmax和SULpeak的平均相对差异分别为4.3%和6.7%,可重复性系数上下限分别为SUVmax 19.4%和-16.3%、SULpeak 21.2%和-17.5%。将SULpeak可重复性系数阈值应用于第二队列28例146处骨病灶,较PERCIST ±30% SULpeak标准改变了3例患者的状态。
要点
- 骨病灶18F-FDG SUVmax下降超过17%和升高超过20%不太可能由测量变异所致
- SUVmax和SULpeak平均相对差异分别为4.3%和6.7%
- SULpeak可重复性系数标准较PERCIST ±30% SULpeak改变了3例患者的状态
核心结论
- 使用18F-FDG SUVmax评估骨优势转移乳腺癌患者骨肿瘤反应时,重测研究的可重复性系数显示下降超过17%和升高超过20%不太可能由测量变异所致。
- 在探究此类患者骨病灶的临床试验(如ECOG-ACRIN EA1183试验)中,系列18F-FDG显像可受益于允许解读反应的可信限。
研究设计与样本
- 前瞻性评估乳腺癌骨优势转移患者18F-FDG重测摄取变异性的研究。
- 第一队列9例患者38处骨病灶,在同一校准扫描仪上14天内两次行18F-FDG显像,量化SUVmax和SULpeak。
- 第二队列28例乳腺癌骨优势转移患者146处转移骨病灶,在标准治疗前后行18F-FDG显像以评估反应。
主要发现
- 第一队列38处骨肿瘤中SUVmax和SULpeak的平均相对差异分别为4.3%和6.7%。
- SUVmax可重复性系数上下限分别为19.4%和-16.3%,SULpeak分别为21.2%和-17.5%。
- 第二队列按SULpeak可重复性系数可信限分层为11例进展、5例稳定、7例部分缓解、1例完全缓解,3例无法评估。
- SULpeak可重复性系数反应标准较PERCIST ±30% SULpeak标准改变了3例患者的状态。
关键数值与推荐
- SUVmax可重复性系数上下限为19.4%和-16.3%。
- SULpeak可重复性系数上下限为21.2%和-17.5%。
- SUVmax下降超过17%和升高超过20%不太可能由测量变异所致。
- PERCIST标准为SULpeak ±30%。
临床怎么用
- 原文结论指出,在评估此类患者骨肿瘤反应时,SUVmax下降超过17%和升高超过20%不太可能由测量变异所致。
- 原文结论指出,探究此类患者骨病灶的临床试验系列18F-FDG显像可受益于允许解读反应的可信限。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Standard measures of response such as Response Evaluation Criteria in Solid Tumors are ineffective for bone lesions, often making breast cancer patients that have bone-dominant metastases ineligible for clinical trials with potentially helpful therapies. In this study we prospectively evaluated the test-retest uptake variability of 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) in a cohort of breast cancer patients with bone-dominant metastases to determine response criteria. The thresholds for 95% specificity of change versus no-change were then applied to a second cohort of breast cancer patients with bone-dominant metastases. METHODS: For this study, nine patients with 38 bone lesions were imaged with 18F-FDG in the same calibrated scanner twice within 14 days. Tumor uptake was quantified by the most commonly used PET parameter, the maximum tumor voxel normalized by dose and body weight (SUVmax) and also by the mean of a 1-cc maximal uptake volume normalized by dose and lean-body-mass (SULpeak). The asymmetric repeatability coefficients with confidence intervals for SUVmax and SULpeak were used to determine the limits of 18F-FDG uptake variability. A second cohort of 28 breast cancer patients with bone-dominant metastases that had 146 metastatic bone lesions was imaged with 18F-FDG before and after standard-of-care therapy for response assessment. RESULTS: The mean relative difference of SUVmax and SULpeak in 38 bone tumors of the first cohort were 4.3% and 6.7%. The upper and lower asymmetric limits of the repeatability coefficient were 19.4% and - 16.3% for SUVmax, and 21.2% and - 17.5% for SULpeak. 18F-FDG repeatability coefficient confidence intervals resulted in the following patient stratification using SULpeak for the second patient cohort: 11-progressive disease, 5-stable disease, 7-partial response, and 1-complete response with three inevaluable patients. The asymmetric repeatability coefficients response criteria for SULpeak changed the status of 3 patients compared to the standard Positron Emission Tomography Response Criteria in Solid Tumors of ± 30% SULpeak. CONCLUSION: In evaluating bone tumor response for breast cancer patients with bone-dominant metastases using 18F-FDG SUVmax, the repeatability coefficients from test-retest studies show that reductions of more than 17% and increases of more than 20% are unlikely to be due to measurement variability. Serial 18F-FDG imaging in clinical trials investigating bone lesions in these patients, such as the ECOG-ACRIN EA1183 trial, benefit from confidence limits that allow interpretation of response.
引用
- Muzi M, Peterson LM, Specht JM, et al. Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials. EJNMMI Res. 2024. PMID: 38536511. doi:10.1186/s13550-024-01093-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。